Table of Content

25 October 2024, Volume 16 Issue 5 Previous Issue    Next Issue

Select

Expert consensus on radiotherapy combined with immunotherapy for non-small cell lung cancer (2024 edition) Integrated Oncology Branch of Chinese Anti-cancer Association, Tumor Marker Committee of Chinese Anti-cancer Association 2024, 16 (5):  505-515.  doi: 10.3969/j.issn.1674-5671.2024.05.01 Abstract ( 850 )   PDF   Save Related Articles | Metrics

Select

Application and challenge of CAR-T cell therapy in autoimmune diseases LI Siyuan, ZHANG Yan, ZHANG Lu 2024, 16 (5):  516-524.  doi: 10.3969/j.issn.1674-5671.2024.05.02 Abstract ( 338 )   PDF   Save Chimeric antigen receptor T (CAR⁃T) cell therapy endows patients' autologous T cells with the ability to specifically recognize and kill tumor cells through gene editing technology, which has achieved remarkable results in tumor immunotherapy in recent years. With the continuous development of CAR⁃T cell therapy, its research field has gradually expanded to autoimmune diseases. This article reviews the research progress of CAR⁃T cell therapy in the treatment of autoimmune diseases such as systemic lupus erythematosus, anti⁃synthetase syndrome, and systemic sclerosis, analyzes its efficacy and safety, and investigates the potential of deep B⁃cell depletion and immune system reconstitution. Despite the fact that CAR⁃T cell therapy has shown long⁃term, drug⁃free remission in some refractory patients, it continues to face challenges in terms of production difficulty, safety and durability. Future research will focus on improving personalized treatment to promote disease management and minimize adverse effects.  Related Articles | Metrics

Select

Current status and progress of CAR-T cell therapy in multiple myeloma WU Jialu, GE Xia, CHEN Wenming, YANG Guangzhong 2024, 16 (5):  525-531.  doi: 10.3969/j.issn.1674-5671.2024.05.03 Abstract ( 248 )   PDF   Save Multiple myeloma (MM) is an incurable haematological malignancy of the blood system. For patients suitable for transplantation, autologous stem cell transplantation (ASCT) can significantly enhance the rate of remission and prolong progression⁃free survival. Over the past decade, with a deeper understanding of the disease biology and advances in therapeutic approaches, many MM patients have been able to control disease and improve their quality of life, but they ultimately face the relapse. For patients with relapsed/refractory MM, chimeric antigen receptor T (CAR⁃T) cell therapy has demonstrated notable efficacy and superior safety, significantly delaying disease progression. This review focuses on the current status and progress of CAR⁃T cell therapy in the treatment of MM, as well as the reasons for its failure, to provide new ideas for the further development of CAR⁃T cell therapy in MM.  Related Articles | Metrics

Select

Advances in the application of molecular targeted drugs combined with CAR-T cell therapy in lymphoma LI Mengjiao, CEN Yali, DOU Baitao, SHU Rou, LI Yanling, QIU Ling, REN Shihui, YAO Hao, FAN Fangyi 2024, 16 (5):  532-539.  doi: 10.3969/j.issn.1674-5671.2024.05.04 Abstract ( 189 )   PDF   Save The efficacy of chimeric antigen receptor T (CAR⁃T) cell therapy has been confirmed in the treatment of lymphoma, but challenges such as resistance, safety and adverse reactions impacted prognosis in some patients. Molecular targeted drugs can regulate the tumor microenvironment and enhance tumor⁃specific antigen expression, and help to reduce the occurrence of antigen escape. Some small molecule targeted drugs can induce tumor cell death by regulating the balance between anti⁃apoptotic and pro⁃apoptotic signaling pathways. Additionally, these drugs can also regulate the immune suppression and activation pathways to improve the anti⁃tumor efficacy of CAR⁃T cell therapy, reverse the exhaustion of CAR⁃T cell, and enhance their anti⁃tumor effects. The efficacy, safety, and mechanisms of action involved in combining molecular targeted drugs with CAR⁃ T cell therapy in lymphoma treatment have garnered increasing attention. In this paper, the research progress of the combination of CAR⁃ T cell therapy with commonly used molecular targeted drugs in the treatment of lymphoma was reviewed. Related Articles | Metrics

Select

Strategies for prevention,control and management of CAR-T cell therapy related adverse reactions LIU Jingqian, ZHANG Yajing 2024, 16 (5):  540-548.  doi: 10.3969/j.issn.1674-5671.2024.05.05 Abstract ( 256 )   PDF   Save Chimeric antigen receptor T (CAR⁃T) cell therapy, as a novel tumor immunotherapy, has achieved remarkable results in the treatment of relapsed/refractory hematological malignancies. However, the occurrence of CAR⁃T cell therapy⁃related adverse reactions has impacted its clinical benefits. This article reviews the classification and characteristics, risk factors, monitoring and assessment, preventive measures, and recent advancements in management of CAR⁃T cell therapy⁃related adverse reactions. It also summarizes the current status and challenges the management of CAR⁃T cell therapy⁃related adverse reactions and looks forward to future research directions, aiming to provide clinicians with the latest research progress and practical guidance in this field to promote the safe and effective application of CAR⁃T cell therapy. Related Articles | Metrics

Select

Clinical characteristics of patients with relapsed/refractory multiple myeloma after CAR-T cell therapy  WANG Huijuan, CHEN Wenming, GENG Chuanying, YANG Guangzhong 2024, 16 (5):  549-553.  doi: 10.3969/j.issn.1674-5671.2024.05.06 Abstract ( 128 )   PDF   Save Objective To analyze the clinical characteristics of patients with relapsed/refractory multiple myeloma (RRMM) after CAR⁃T cell therapy, and to explore the possible effective strategies for such patients in the future. Methods Patients with RRMM who were hospitalized in Beijing Chao⁃Yang Hospital, Capital Medical University from January 2020 to June 2024 were selected as the study subjects, and clinical characteristics and survival and survival after CAR⁃T cell therapy were analyzed. Results A total of 14 eligible RRMM patients who collected by the medical record system received CAR⁃T cell therapy targeting BCMA, with the median progression⁃free survival (PFS) of 17 months (range: 3-47 months）. At the time of disease recurrence and progression, 1 patient had extramedullary relapse, 2 patients developed secondary plasma cell leukemia,and 11 patients were intramedullay recurrence. Cytogenetics was examined in 7 patients, of which 4 patients with 1 high⁃risk gene, 1 patient with two high⁃risk genes. In the first salvage regimens, the commonly used agents included Daratumumab (6 cases）, Pomalidomide (5 cases）, and Carfilzomib (3 cases), and 3 patients were enrolled in the clinical trials. Among the 13 evaluable  patients, the overall response rate was 61.5% (8/13）, with a complete response rate of 30.8% (4/13) and a very good partial response rate of 23.1% (3/13）. The median follow⁃up time was 15 months (range: 1-32 months）, and the median PFS was 7 months. As of the last follow⁃up, 6 patients died. The median overall survival was 32 months. 1 patient developed a secondary malignance (lung cancer）. Conclusions Patients with RRMM receiving CAR⁃T cell therapy have a poor response to the currently available agents at the time of relapse and progression.  Related Articles | Metrics

Select

Safety of CD19 CAR-T therapy: Signal mining and analysis of adverse events based on FAERS database SUN Yifei, GAO Wen, JIA Junlei, ZHANG Huilai, YU Jingwei, WANG Xianhuo 2024, 16 (5):  554-561.  doi: 10.3969/j.issn.1674-5671.2024.05.07 Abstract ( 146 )   PDF   Save Objective To analyze the adverse effects (AEs) of CD19 chimeric antigen receptor T (CAR⁃T) cell drugs on the market , so as to provide evidence for clinical treatment. Methods The United States Food and Drug Administration's adverse event reporting system (FAERS) database was used to obtain the baseline data and the AE results of four marketed CD19 CAR⁃T drugs from the first quarter of 2017 to the fourth quarter of 2023 after data retrieval, screening, deduplication, collation and analysis. The reporting odds ratio (ROR) and proportional ADR reporting ratio (PRR) were used to analyze and compare the AE results. Results A total of 5, 335 reports of 4 marketed CD19 CAR⁃T drugs included Axicabtagene ciloleucel (Axi⁃cel）, Tisagenleucel (Tisa⁃cel）, Brexucabtagene autoleucel (Brexu⁃cel) and Lisocabtagene maraleucel (Liso⁃cel) were obtained from the FAERS database. The proportion of the four CD19 CAR⁃T drugs in males was higher than that in females; the age distribution was above 18 years old; and the body weight was mostly concentrated in 50-100 kg. CD19 CAR⁃T drugs were involved in 23 types of system organ classification (SOC）, mainly focusing on neurological diseases and immune system diseases, among which cytokine release syndrome (CRS) and immune effector cell⁃associated neurotoxicity syndrome (ICANS) were the most common. In addition, some AEs not listed in the label were also found in this study, such as myelodysplastic syndromes (MDS）, acute kidney injury (AKI）, and sepsis. Conclusions In clinical practice, attention should also be paid to the possible unlisted AEs, such as MDS, AKI and sepsis, in addition to the AEs mentioned in the drug label.  Related Articles | Metrics

Select

BCMA CAR-T cell therapy for relapsed/refractory plasmablastic lymphoma: case report and clinical implication LYU Liwei, CONG Jia, WU Yiping, WANG Liang 2024, 16 (5):  562-565.  doi: 10.3969/j.issn.1674-5671.2024.05.08 Abstract ( 118 )   PDF   Save Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of large B⁃cell lymphoma, with a poor prognosis without standardized treatment protocols. Traditional therapeutic strategies, such as chemotherapy, proteasome inhibitors, immunomodulatory agents, CD30 and CD38 monoclonal antibodies, and autologous hematopoietic stem cell transplantation, have yielded suboptimal outcomes. Chimeric antigen receptor T (CAR⁃T) cell therapy has revolutionized the management of diffuse large B⁃cell lymphoma and multiple myeloma, offering hope for patients with PBL. However, clinical experience and data evidence supporting the application of CAR⁃T cell in PBL treatment remain scant. This paper reports a case of an elderly patient with PBL who achieved a complete response following B⁃cell maturation antigen CAR⁃T cell therapy.  Related Articles | Metrics

Select

Glofitamab therapy under the dual challenge of novel coronavirus infection and CAR-T resistance: a case report of refractory diffuse large B-cell lymphoma BI Jianghan, ZHANG Yan, WANG Wei 2024, 16 (5):  566-570.  doi: 10.3969/j.issn.1674-5671.2024.05.09 Abstract ( 132 )   PDF   Save The data of a patient with refractory diffuse large B⁃cell lymphoma, who was failed to chimeric antigen receptor T (CAR⁃T) cell therapy, are analyzed in this report. The patient achieved complete remission after receiving glofitamab with combination of coronavirus disease 2019 (COVID⁃19), and no other serious adverse events such as aggravation of COVID⁃19 were observed. Meanwhile, the efficacy of Glofitamab in the treatment of refractory diffuse large B⁃cell lymphoma is reviewed, and the safety of bispecific antibodies in patients with lymphoma complicated with COVID⁃19 is evaluated. Related Articles | Metrics

Select

CD19 CAR T-cell therapy: a case of refractory primary central nervous system diffuse large B-cell lymphoma HE Ying, LI Mengjiao, CEN Yali, DOU Baitao, SHU Rou, LI Yanling, YAO Hao, FAN Fangyi 2024, 16 (5):  571-576.  doi: 10.3969/j.issn.1674-5671.2024.05.10 Abstract ( 162 )   PDF   Save Primary central nervous system lymphoma (PCNSL) is a rare type of extranodal non⁃Hodgkin's lymphoma that exclusively involves the central nervous system (CNS）. Previous studies have shown that chimeric antigen receptor T (CAR⁃T) cell therapy can improve the depth of remission and survival outcomes in patients with PCNSL. CD19 CAR⁃T cell therapy has been successful in treating a various of B⁃cell lineage malignancies, but has been limited in treating B cell non⁃Hodgkin lymphoma presenting in the CNS, primarily due to potential toxicity. This paper reported a case of PCNSL who did not develop any grade of cytokine release syndrome or immune effector cell⁃related neurotoxicity syndrome after CD19 cell CAR⁃T cell therapy and achieved complete remission, and it can provide a reference for the clinical treatment of this type of patients. Related Articles | Metrics

Select

Comparative analysis of molecular characteristics of constitutive activation of NRAS and CTNNB1  in liver cancer WANG Xingchen, LIAO Dawen, LI Jiaying, SUN Xiacheng, BI Qian, Huang Qichao, HUANG Jiangtao 2024, 16 (5):  577-585.  doi: 10.3969/j.issn.1674-5671.2024.05.11 Abstract ( 181 )   PDF   Save Objective To compare the differences in molecular biological characteristics and the signal transduction networks of liver cancer  induced by constitutive activation of NRAS and CTNNB1, as well as to investigate potential therapeutic strategies. Methods The expression of NRAS and CTNNB1 in liver cancer tissues and their relationship with patients prognosis were analyzed using public data. The mixed plasmids of NRasV12/myr⁃Akt/pCMV⁃SB and N90⁃β⁃catenin/myr⁃Akt/pCMV⁃SB were introduced into mice by a hydrodynamic tail vein injection, and the liver cancer tissues were obtained after 4 weeks. Transcriptome sequencing and bioinformatics analysis were employed to analyze the differential genes and signal networks in liver cancer with NRAS and CTNNB1 constitutively activated. NRAS related  liver cancer mice and CTNNB1 related  liver cancer mice were continuously supplemented with 1.5 g/L L⁃alanine through drinking water until the end of the observation period for 90 days , and the corresponding control group mice were given normal drinking water. The survival status, body weight and liver weight of the mice were recorded. Results The expression of NRAS and CTNNB1 in liver cancer tissues was significantly up⁃regulated as compared with those in normal liver tissues (all P<0.001), and the survival rate of patients with high expression of NRAS and CTNNB1 was lower than that of patients with low expression (all P<0.01).  KEGG analysis revealed that the constitutive activation of both oncogenes could regulate the cell cycle, but the alterations in amino acid metabolism were particularly pronounced in NRAS constitutively activated liver cancer tissues. Supplementation with L⁃alanine significantly prolonged the survival time of the mice with NRAS constitutive activation (P<0.001) and reduced the liver⁃to⁃body weight ratio (P<0.05). However, continuous supplementation of L⁃alanine did not significantly improve the survival time and liver⁃to⁃body weight ratio of the mice with CTNNB1 constitutive activation (all P>0.05). Conclusions The molecular biological characteristics induced by constitutive activation of NRAS and CTNNB1 are significantly different in liver cancer. Intervention of  amino acid metabolism may be a potential therapeutic strategy for NRAS related liver cancer, but there is no significant benefit for CTNNB1 related liver cancer. Related Articles | Metrics

Select

Construction of recombinant plasmid of AGK gene promoter and its transcriptional activity in T lymphocyte leukemia XIAO Xiaoyinan, WANG Ruikun, HAN Meng, LIU Sihan, ZHUO Fangqi, CHEN Minkuan, DU Yimeng, CHE Yongsheng, XU Xiaojie 2024, 16 (5):  586-592.  doi: 10.3969/j.issn.1674-5671.2024.05.12 Abstract ( 154 )   PDF   Save Objective To investigate the upstream transcription mechanism of acylglycerol kinase (AGK) in T lymphocyte leukemia, construct recombinant plasmids with different truncated fragments of the AGK gene promoter and detect their transcriptional activity. Methods Public databases such as TIMER2.0, The Human Protein Atlas, and Gene Expression Profiling Interactive Analysis were used to explore the role of AGK in non⁃solid tumors. Using the pGL4. 20⁃pAGK promoter luciferase full⁃length plasmid as a template, PCR was used to amplify truncated fragments of different lengths of the AGK promoter. The amplified fragments were inserted into the pGL4. 20⁃basic vector respectively to construct recombinant plasmids with different truncated fragments of the AGK promoter. After double enzyme digestion and sequence identification were correct, the recombinant plasmid was electroporated and transfected into human T lymphocytic leukemia cell Jurkat, and the dual⁃luciferase reporter gene assay was used to determine the dual luciferase activity of different truncated fragments of the AGK promoter. Results The expression of AGK was up⁃regulation in a variety of tumor types (P<0.05), and the expression level of AGK in leukemia cells was at a higher level. Log⁃rank test showed that the overall survival of patients with high AGK expression was lower than that of patients with low AGK expression (P=0.028）. Three high⁃scoring binding regions of transcription factor TEAD and AGK were predicted by JASPAR website, and the recombinant plasmids containing different truncated fragments of the AGK gene promoter were successfully constructed. Dual luciferase reporter gene assay showed that the transcriptional activity of AGK promoter was higher in the -540 bp to -80 bp region in T lymphocyte leukemia cells. Conclusions The transcription activity of the AGK gene promoter in the -540 bp to -80 bp region was higher in human T lymphocytic leukemia cells, laying the foundation for further research on the transcription and upstream regulatory mechanisms of AGK in T lymphocyte leukemia. Related Articles | Metrics

Select

Trend of the incidence of gastric cancer in China,1992—2021 DONG Junling, YANG Hui, LI Na 2024, 16 (5):  593-597.  doi: 10.3969/j.issn.1674-5671.2024.05.13 Abstract ( 591 )   PDF   Save Objective To analyze the current status and changing trend of the incidence of gastric cancer in Chinese residents from 1992 to 2021, and to assess the influence of age, period and cohort on its long⁃term trend, so as to provide a scientific reference for the formulation of gastric cancer prevention and treatment strategies in China.Methods By using data from the Global Burden of Disease 2021 (GBD 2021) database on the incidence of gastric cancer in Chinese residents from 1992 to 2021, the effects of age, period and cohort on the incidence were evaluated based on an age⁃period⁃cohort model.Results From 1992 to 2021, the incidence of gastric cancer in China showed an increasing trend, from 34.35/105 in 1992 to 43.00/105 in 2021, with an average annual increase of 0.79% (95%CI: 0.74%-0.83%). The age⁃effect results of age⁃period⁃cohort model showed that the incidence increased with the increase of age, and reached its peak at 85-89 years old (207.42/105, 95%CI: 197.18/105-218.20/105）.The period⁃effect results showed that the incidence risk of gastric cancer decreased with the passage of time.The incidence risk of gastric cancer was the lowest in 2017—2021 with 2002—2006 as the control group (RR=0.69, 95%CI: 0.67-0.71）.Cohort⁃effect results showed the birth cohort from 1952 to 1956 was used as the control group, and the birth cohort from 2002 to 2006 had the lowest risk (RR=0.40, 95%CI: 0.17-0.91）. Conclusions The incidence of gastric cancer is increasing in China, the elderly population is at a higher risk, and the males in the late birth cohort are at a higher risk than females. Corresponding measures should be taken to further reduce the disease burden of gastric cancer. Related Articles | Metrics

Select

Efficacy and safety of Fruquintinib combined with immune checkpoint inhibitors in later-line treatment of patients with microsatellite stable metastatic colorectal cancer ZHAO Wensi, KE Shaobo, CHEN Jiamei, WU Yong, ZHANG Caiyutian, CHEN Yongshun 2024, 16 (5):  598-605.  doi: 10.3969/j.issn.1674-5671.2024.05.14 Abstract ( 145 )   PDF   Save Objective To evaluate the efficacy and safety of fruquintinib alone or in combination with immune checkpoint inhibitor (ICI) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC)in third⁃line or above treatment. Methods Patients with pMMR/MSS type mCRC admitted to the Department of Oncology, Renmin Hospital of Wuhan University, from January 2020 to April 2024 were selected as the research objects. The prognoses, efficacies and safeties of fruquintinib alone and in combination with ICI were compared in the unadjusted model and the propensity score matching. Results A total of 104 patients were included in the analysis, 33 in the fruquintinib group and 71 in the fruquintinib combined with ICI group. Compared to the fruquintinib group, the median progression⁃free survival was longer in the fruquintinib combined ICI group (3.0 months vs 4.5 months; HR=0.55, 95%CI: 0.33-0.89）. However, there were no significant differences in the median overall survival (10.1 months vs 13.1 months）, the objective response rate (9.1% vs 11.3%) and the disease control rate (51.5% vs  66.2%)between the two groups (all P>0.05）. Similar results were obtained in the analysis of the propensity score matching. The adverse events of grade 3 or above in both groups mainly included hand⁃foot⁃skin reaction, thrombocytopenia and leukopenia. The incidence of grade 3 or above adverse events was 30. 3% in the fruquintinib group and 36.6% in the fruquintinib combined with ICI group (P=0.529）. Conclusions Compared with fruquintinib, fruquintinib combined with ICI provides benefits in the progression⁃free survival for pMMR/MSS type mCRC patients in third⁃line or above treatment with controllable safety, which is worthy of further study. Related Articles | Metrics

Select

Hotspots and trends of research on early esophageal cancer treatment：visual analysis based on CiteSpace ZHAO Min, LI Rongrong, LI Boyan, WANG Wenchang, DU Shengyan, YANG Junhan, LI Huaihao, BAO Yinghui, SHI Yueting, HE Yao, LIU Miao 2024, 16 (5):  606-605.  doi: 10.3969/j.issn.1674-5671.2024.05.15 Abstract ( 136 )   PDF   Save Objective To analyze the research status and trends of early esophageal cancer treatment, and to provide guidance for promoting cutting-edge research on early esophageal cancer treatment. Methods Bibliometric analysis was used to screen the relevant literatures included in the Chinese National Knowledge Infrastucture (CNKI), China Biology Medicine (CBM), Web of Science core database and PubMed database from January 1, 2013, to December 31, 2023. CiteSpace 6.3. R1 software was used to visually analyze the annual publication volume, authors and keywords of the included literatures. Results A total of 1,752 Chinese literatures and 997 English literatures were included. From 2013 to 2021, the number of Chinese literature publications on early esophageal cancer treatment constantly exceeded 100 articles each year, surpassing the number of English literature. In contrast, the number of articles published by the top five authors in English (all ≥35 articles)was higher than that of the top five authors in Chinese (all ≥5 articles), with a higher degree of collaboration among authors. The analysis of research hotspots and collaboration status indicated that institutions such as Peking Union Medical College and the Chinese People's General Hospital had made significant contributions to the research in this field . However, the connection among research teams in China were relatively weak, while foreign authors demonstrated closer collaboration. Keyword analysis revealed that frequently used words such as "Endoscopic", "Efficacy" and "Precancerous lesion" were prevalent in Chinese literature. In English literature, keywords like "Therapy", "Mucosal resection" and "Endoscopic mucosal resection" were more frequently mentioned. Furthermore, mutation analysis indicated a growing focus on the quality control and safety in treatment both domestically and internationally. Conclusions The treatment of early esophageal cancer is a prominent area of research both domestically and interna tionally, and researchers should strengthen cooperation. Future research of the treatment of early esophageal cancer may be focused on treatment methods, complications associated with treatment, recurrence rates, and risk factors. Related Articles | Metrics

Select

Summary of evidence for the management of drug-related symptoms during endocrine therapy in breast cancer patients ZHANG Xiaomeng, WANG Yue, WAN Qiaoqin 2024, 16 (5):  615-621.  doi: 10.3969/j.issn.1674-5671.2024.05.16 Abstract ( 127 )   PDF   Save Objective To search, evaluate and integrate the best evidence for the management of drug⁃related symptoms during endocrine therapy in breast cancer patients, so as to provide reference for clinical practice. Methods According to the "6S" model of evidence⁃based resources, computer⁃aided literature search was conducted on BMJ Best Practice, Up To Date, Website of World Health Organization (WHO）, Guidelines International Network (GIN）, PubMed, CNKI, and Wanfang Database. The types of literature covered guidelines, systematic review/Meta⁃analysis, evidence summary, clinical decision⁃making, and expert consensus. The search period was from the establishment of the database to April 2023. Two evidence⁃based professionals evaluated the quality of the included literatures and extracted the data. Results A total of 16 references were included, including 3 clinical decision⁃makings, 2 guidelines, 1 expert consensus, and 10 systematic reviews. A total of 27 pieces of the best evidence of drug⁃related symptom management in endocrine therapy for breast cancer patients were summarized with respect to 6 aspects, including risk assessment, individualized management, general symptom management strategy, drug intervention, non⁃drug intervention, and cognitive behavioral intervention. Conclusions The 27 pieces of summarized evidence can be used for the symptom management of drug⁃related side effects in endocrine therapy in breast cancer patients, and specific evidence should be selected according to cultural background, clinical situation, patient's symptoms and willingness. Related Articles | Metrics

Select

Status quo and reflections on psychological pain and psychotherapy in patients with advanced breast cancer ZHANG Yening, PANG Ying, HE Yi, TANG Lili 2024, 16 (5):  622-628.  doi: 10.3969/j.issn.1674-5671.2024.05.17 Abstract ( 214 )   PDF   Save Related Articles | Metrics

Select

Research progress of fibrinogen as a predictor of curative effect and prognosis of lung cancer YU Degang, JIA Junmei 2024, 16 (5):  628-632.  doi: 10.3969/j.issn.1674-5671.2024.05.18 Abstract ( 148 )   PDF   Save Related Articles | Metrics